The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2022 Summer Meeting | Updates in lung cancer management from the BTOG 2022 Summer Meeting
Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, UK, shares highlights from the BTOG 2022 Summer Meeting, including discussion surrounding the management of early lung cancer and the Phase III CHECKMATE-816 (NCT02998528) and NADIM (NCT03838159) trials showing promising data supporting the neoadjuvant treatment of lung cancer. This interview took place at the BTOG 2022 Summer Meeting congress in London.
